It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.95 [0.41, 2.17]
2 studies · 247 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ SCD‐related SAEs

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 195 participants
Very low

Deferasirox vs deferiprone (DFO)

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
0.96 [0.06, 15.42]
2 studies · 240 participants
Very low

DFX film‐coated tablet vs DFX dispersible tablet

Adherence to iron chelation therapy (%, SD)

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 91 participants
Very low

DFX film‐coated tablet vs DFX dispersible tablet

Sustained adherence to iron chelation therapy (%, SD)

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

DFX film‐coated tablet vs DFX dispersible tablet

SAEs

It is very uncertain whether summary of findings: Comparison 4 ‐ deferasirox (DFX) film‐coated… changes incidence of SAEs compared with DFX dispersible tablets (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 1.22 [0.62, 2.37]
1 study · 173 participants
Very low

DFX film‐coated tablet vs DFX dispersible tablet

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
7.3 [0.14, 368.15]
1 study · 173 participants
Very low

DFX film‐coated tablet vs DFX dispersible tablet

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found